The story of Sildenafil presents a complex case for stakeholders in the medicinal sector. While initially a phenomenal success, generating billions, the patent end and the subsequent entry of off-brand alternatives https://adult679089.tribunablog.com/the-little-copyright-and-pharma-a-hazardous-investment-56475608